LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)

31-10-2017

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom. LeadArtis is a partner in the Immunostimulatory Agonist Antibodies for Cancer Therapy effort, a 6.9M€ funding initiative which incorporates long-standing expertise in agonist immunostimulatory antibodies (IS-Abs) from research institutions and small-medium enterprises (SEM) in five European countries (Germany, Italy, Spain, Sweden and United Kingdom). The IACT program aims to translate the agonist IS-Ab concept into immune oncology treatments (http://www.iact-project.eu/). Two ongoing clinical trials are pivotal to bring forward the pre-clinical Proof of Concept. Analogous SME-driven effort aims at the development of 2nd generation agonist IS-Abs with superior therapeutic index. LeadArtis is applying its Biespecific TrimerbodyTM technology for the generation of novel tumor targeting immune stimulating multivalent antibodies.

Latest News

Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...

Medical oncologist Dr. Luis Paz-Ares MD, Ph.D joins Leadartis´ scientific advisory board
10-12-2018

Luis Paz-Ares MD, PhD. Chair of the Medical Oncology Department at the Hospital 12 de Octubre,...

Nature Communications: LeadArtis outlines a new bispecific antibody that could hold the key to activate cancer killer T-cells to find and destroy highly prevalent tumors
17-11-2018

LeadArtis and collaborators have published in the highly regarded scientific journal Nature...